33
Participants
Start Date
July 31, 2025
Primary Completion Date
June 30, 2030
Study Completion Date
June 30, 2030
surgery/chemotherapy
secondary cytoreductive surgery followed by 6 cycles of post-operative chemotherapy
Iparomlimab/Tuvonralimab
Iparomlimab/tuvonralimab will be administered at a dose of 5 mg per kilogram IV every 21 days. Treatment will continue until disease progression confirmed by RECIST criteria v1.1, intolerable toxicity or withdrawal of consent.
Zhongshan Hospital Fudan University, Shanghai
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Shanghai Zhongshan Hospital
OTHER
Tongji Hospital
OTHER
Shanghai Gynecologic Oncology Group
OTHER_GOV